Heterogeneity of cognitive progression and clinical predictors in Parkinson’s disease–subjective cognitive decline

Abstract Background Parkinson’s Disease (PD)-associated subjective cognitive decline (PDSCD) is defined as cognitive complaints without objective cognitive impairment. Based on most studies, it is associated with a greater risk of cognitive decline and may represent a prodromal stage of cognitive impairment. Methods The main objectives are to identify cognitive progression patterns and clinical predictors of worse cognitive decline within a large PD-SCD cohort with a 4-year followup. All patients belong to the prospective observational multicenter study COPPADIS. Results A total of 198 PD-SCD subjects were analyzed. Mean age was 60.9, mean disease duration 5.2, and mean PD-Cognitive Rating Scale (PD-CRS) 97.6. Subjects were classified as Progressors if their Reliable Change Index was ≤ − 1.64 at year 4, and as non-Progressors if it was > − 1.64 (− 1.64 corresponded to − 16 on the PD-CRS). Progressors had significantly higher age, Movement Disorders Society-Unified PD Rating Scale (MDS-UPDRS) III, levodopa equivalent daily-dose, Non-Motor Symptom Scale total score, memory-related cognitive complaints, and prevalence of REM-sleep behavior disorder (RBD) at baseline. A linear mixed-effects model showed divergent cognitive trajectories between Progressors and non-Progressors (estimate = − 26.8; p < 0.001), with no differences in motor trajectories. In the binary regression model, age (OR = 1.09; p = 0.001), MDS-UPDRS III (OR = 1.05, p = 0.008), and RBD (OR = 2.55, p = 0.010) at baseline were independent predictors of cognitive progression. Conclusions Subjects with PD-SCD do not consistently show cognitive decline, but rather exhibit a heterogeneous progression. Age, MDS-UPDRS III and RBD significantly increase the risk of a more aggressive cognitive phenotype. Future research on biomarkers will help explore additional cognitive predictors in PD-SCD.

Authors

Institutions

Publication Details

Journal
Journal of Neurology
Published
2025-03-01
DOI
https://doi.org/10.1007/s00415-024-12808-0
Citations
5
Primary Topic
Parkinson's Disease Mechanisms and Treatments
Type
article
Field-Weighted Citation Impact
6.95

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Heterogeneity of cognitive progression and clinical predictors in Parkinson’s disease–subjective cognitive decline

M. T. Meitín, P. Gámez, J. Muñoz, M. Lage Castro et al.
5 citations
Journal of Neurology
Parkinson's Disease Mechanisms and Treatments
6.95
article

Heterogeneity of cognitive progression and clinical predictors in Parkinson’s disease–subjective cognitive decline

M. T. Meitín, P. Gámez, J. Muñoz, M. Lage Castro, N. Bernardo Lambrich, Bárbara Vives, Diego Santos‐García, Isabel Pareés, C. Méndez del Barrio, Ignacio Álvarez, Silvia Jesús, M. Sánchez-Carpintero, Sonia Escalante, Elena Erro, B. López Seoane, Isabel González Aramburu, Víctor Gómez Mayordomo, Jaime Aneiros Pereira, S. Novo Ponte, Pablo Mir, J. C. Segundo Rodríguez, J. Miranda Santiago, E. Suárez Castro, Mercedes Pueyo Morlans, Erik Jesús Huánuco Casas, Antonio Moreno Diéguez, María Isabel Morales‐Casado, M. Sierra Peña, Pilar Santacruz, M. Botí, Pau Pástor, M. A. Prats, Mónica Kurtis, Jon Infante, Marta Blázquez Estrada, A. Crespo Cuevas, A. Planas-Ballvé, A. Cots Foraster, C. Prieto Jurczynska, Oriol de Fàbregues, Pedro Clavero, M. A. Ávila, Carolina Cabello, J. González Aloy, N. Redondo Rafales, Julio Dotor García‐Soto, F. J. Carrillo Padilla, Núria López Ariztegui, A. Cámara Lorenzo, María G. Alonso Losada, R. Pérez Noguera, Marta Almería, A. Pérez Fuertes, S. Arnáiz, Z. Mendoza Plasencia, Carmen M. Labandeira, J M García-Moreno, Javier Pagonabarraga, Lorena Méndez, Núria Caballol, Iria Cabo, M. Gallego, M. Ruíz De Arcos, Marina Cosgaya, Sara Lucas Del Pozo, Lydia López Manzanares, Javier Ruiz‐Martínez, Darrian McAfee, Jessica González Ardura, Francisco Agramunt Lacruz, Fernando Alonso Frech, Berta Solano Vila, Arnau Puig‐Davi, G. R. González Toledo, Lydia Vela, S. Lastres Gómez, M. Aguilar, Berta Pascual‐Sedano, Yolanda Macías, Pilar Sánchez Alonso, A. Puig Daví, Saül Martínez‐Horta, Daniel López Domínguez, H. Bejr-Kasem, Inés Legarda, Maríateresa Buongiorno, Andrea Horta‐Barba, M. Grau Solá, Pablo Martínez‐Martín, Jorge Hernández‐Vara, Raquel Alonso Redondo, Jaime Kulisevsky, María Asunción Ávila-Rivera, Juan García Caldentey, Víctor Puente, Carmen Borrué, N. Fernández Guillán, Lluís Planellás, Carlos Ordás, Juan Pablo Tartari, M. J. González Palmás, Luis Vargas, Itziar Gastón, Mónica Díez-Fairén, A. Cortina Fernández, G. Sánchez Díez, F. Carrillo, María Álvarez Saúco, G. Guardia, H. Canfield Medina, M. P. Gómez Garre, A. Ascunce Vidondo, E. Carabajal Pendón, Ángel Rodríguez, Cristina Campos, M. Mata, Juan Carlos Martínez‐Castrillo, Manuel Menéndez‐González, Víctor Nogueira, Carmen García Díez, A. Alonso Cánovas, A. B. Rodríguez Pérez, Teresa de Deus Fonticoba, Carmen Borrué, Esther Cubo, A. D. Adarmes, Manuel Seijo, Clara Villanueva, T. de Deus Fonticoba, Maria G. Alonso Losada, B. González García, Adam Diaz, M. J. Martí, I. Muro García, Sonia López Arribas, F Pérez Roldán, M. J. Catalán, M. A. Labrador, L. M. López Díaz, D. Idoate Calderón, Zebenzui Mendoza, A. Novo Amado, Esther Cubo, E. Estelrich Peyret, C. Valero, Caridad Valero, Berta Solano Vila
article en
5 citations

Abstract

Abstract Background Parkinson’s Disease (PD)-associated subjective cognitive decline (PDSCD) is defined as cognitive complaints without objective cognitive impairment. Based on most studies, it is associated with a greater risk of cognitive decline and may represent a prodromal stage of cognitive impairment. Methods The main objectives are to identify cognitive progression patterns and clinical predictors of worse cognitive decline within a large PD-SCD cohort with a 4-year followup. All patients belong to the prospective observational multicenter study COPPADIS. Results A total of 198 PD-SCD subjects were analyzed. Mean age was 60.9, mean disease duration 5.2, and mean PD-Cognitive Rating Scale (PD-CRS) 97.6. Subjects were classified as Progressors if their Reliable Change Index was ≤ − 1.64 at year 4, and as non-Progressors if it was > − 1.64 (− 1.64 corresponded to − 16 on the PD-CRS). Progressors had significantly higher age, Movement Disorders Society-Unified PD Rating Scale (MDS-UPDRS) III, levodopa equivalent daily-dose, Non-Motor Symptom Scale total score, memory-related cognitive complaints, and prevalence of REM-sleep behavior disorder (RBD) at baseline. A linear mixed-effects model showed divergent cognitive trajectories between Progressors and non-Progressors (estimate = − 26.8; p < 0.001), with no differences in motor trajectories. In the binary regression model, age (OR = 1.09; p = 0.001), MDS-UPDRS III (OR = 1.05, p = 0.008), and RBD (OR = 2.55, p = 0.010) at baseline were independent predictors of cognitive progression. Conclusions Subjects with PD-SCD do not consistently show cognitive decline, but rather exhibit a heterogeneous progression. Age, MDS-UPDRS III and RBD significantly increase the risk of a more aggressive cognitive phenotype. Future research on biomarkers will help explore additional cognitive predictors in PD-SCD.

Journal of NeurologyVol. 272(3)
Universitat Autònoma de Barcelona (ES), Hospital Universitario de Canarias (ES), Hospital de Sant Pau (ES), University Hospital Complex Of Vigo (ES), Biomedical Research Networking Center on Neurodegenerative Diseases (ES), Hospital Universitario Virgen Macarena (ES), Centro Oncológico de Galicia (ES), Complejo Hospitalario de Navarra (ES), Hospital Universitario Fundación Alcorcón (ES), Hospital Universitario Rey Juan Carlos (ES), Hospital Universitario Puerta de Hierro Majadahonda (ES), Instituto de Investigación Marqués de Valdecilla (ES), Hospital Clínic de Barcelona (ES), Hospital Universitario de Burgos (ES), Hospital General Universitario de Elche (ES), Hospital Arnau de Vilanova (ES), Instituto Ramón y Cajal de Investigación Sanitaria (ES), Vall d'Hebron Hospital Universitari (ES), Mútua Terrassa (ES), Hospital Universitario de La Princesa (ES), Hospital Del Mar (ES), Hospital de Sant Joan Despí Moisès Broggi (ES), Instituto de Biomedicina de Sevilla (ES), Hospital Universitario Central de Asturias (ES), Biomedical Research Institute (US), Donostiako Unibertsitate Ospitalea (ES), Fundación General (ES), Complexo Hospitalario Universitario A Coruña (ES), Hospital Universitario De Cabueñes (ES), Hospital Ruber Internacional (ES), Hospital Universitari de Tortosa Verge de la Cinta (ES), Hospital Universitario Son Espases (ES), Hospital Universitario Virgen del Rocío (ES), Institut Català de la Salut (ES), Complejo Hospitalario de Pontevedra (ES), Instituto de Investigación Biomédica de A Coruña (ES), Hospital Universitario Infanta Sofía (ES), Institut d'Assistència Sanitària (ES), Hospital Universitario Ramón y Cajal (ES), Complejo Hospitalario Universitario de Toledo (ES), Universidad de Sevilla (ES)
Fundación Científica Asociación Española Contra el Cáncer, Universitat Autònoma de Barcelona, Instituto de Salud Carlos III
Openalex Percentile: Top 3%
Parkinson's Disease Mechanisms and Treatments
6.95
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.